As sterile compounding continues to evolve, driven by both expanding demand and evolving technology, compliance gaps remain a challenge. For some pharmacies, those gaps emerge during periods of growth, such as increased GLP-1 demand, staffing expansion, or facility renovation. For others, they stem from legacy workflows, outdated documentation, or processes that have not been fully aligned with current USP <797> standards.
According to APC’s 2025-2026 annual compounding snapshot, 51% of pharmacies reported increasing staffing or personnel hours to meet GLP-1 demand, while 81% reported investing in facility updates to support USP 797 compliance. But even in pharmacies with stable operations, gaps often persist in training, environmental monitoring, cleaning, and documentation, particularly where longstanding practices have not kept pace with revised standards.
These gaps in 797 compliance not only pose a risk to patient safety but also carry legal risk. In sterile compounding litigation, USP 797 is often treated as the de facto standard of care, even in states where it has not been formally adopted into law. Whether the source is rapid operational change or outdated routine practice, compliance gaps represent not only patient safety risk, but also legal and business exposure.
For that reason, identifying where gaps emerge—and implementing systems to detect, document, and correct them—is essential to maintaining compliance, protecting patients, and reducing risk.
The CORE Framework for USP 797 Compliance
Across FDA Form 483 observations, industry data, and inspector findings, sterile compounding compliance vulnerabilities consistently emerge across four operational domains: Competency, Operations, Records, and Environment (CORE). Identifying these recurring failure points is essential to strengthening compliance, improving process control, and reducing risk.